High Risk and Advanced Upper Tract Urothelial Carcinoma – Still a Role for Surgery
Jennifer A. Linehan, MD explores the treatment of advanced upper tract urothelial carcinoma (UTUC), focusing on therapeutic strategies.
Read More
International Bladder Cancer Update
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the Future
Jennifer A. Linehan, MD, discusses molecular characterization in invasive bladder cancer, molecular profiling, FGFR3 mutations and FGFR inhibitors.
Read More
Immune Checkpoint Inhibitors: Combination Therapy
Jean H. Hoffman-Censits, MD, focuses on studies of PD-1 and PD-L1 inhibitors combined with other agents in bladder cancer treatment.
Read More
Immune Checkpoint Inhibitors: Managing Immune-related Side Effects
Guru P. Sonpavde, MD, explains immune checkpoint inhibitors and their role in activating the immune system to fight cancer.
Read More
The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer
Dr. Daniel P. Petrylak discusses using antibody-drug conjugates (ADCs) in the treatment of advanced urothelial cancer.
Read More